Latest Breaking News On - Product characteristics - Page 3 : comparemela.com

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomBecker hewesMastocytosis advEuropean hematology associationBlueprint medicines corporationEuropean academy of allergyPrnewswire blueprint medicines corporation nasdaqEuropean commissionPatient surveyExchange commissionDrug administrationPatient survey abstractMedicines corporationClinical immunologyHematology associationHybrid congress

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma Following recent consultation with FDA,.

Western australiaUnited kingdomUnited statesMark moyerImmunocore immClayton robertsonImmunocore holdingsExchange commission onRegulatory affairsExchange commissionEuropean unionHead of communicationsAgainst cancerRelease syndromeProduct characteristicsPrivate securities litigation reform act

Helsinn and Angelini Pharma sign a partnership agreement

Helsinn and Angelini Pharma sign a partnership agreement
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Slovak republicCzech republicMelanie rolliChiara antoniucciAngelini pharmaErik lommerdeDaniela poggioFrancesco angeliniHelsinn groupConsumer healthGroup communicationBrain healthAngelini industriesHelsinn group media contactVp international operations at angelini pharmaMental health

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
itnewsonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnewsonline.com Daily Mail and Mail on Sunday newspapers.

United kingdomSan franciscoUnited statesUniversity of chicagoKevin harringtonEli lillyJonathan schoenfeldUniversity of chicago medicineEuropean commissionUniversity of californiaDana farber cancer instituteDrug administrationAmerican society of clinical oncologyInstitute of cancer researchHead of development unitClinical trial program

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

United statesSouth koreaPushkar muthaMariat bourlonTycel jovelle phillipsTony mokLin wangPeter robert galleCharlene mantiaMarc hoffmannEric christensonSuzanne trudelManali kirtikumar kamdarGuillermo garcia maneroMartin reckTina cascone